Publications scientifiques

The adjudication rates between readers in blinded independent central review (BICR) of advanced esophageal cancer trials with or without immune checkpoint initiators as first line therapy

Yan Liu [1], Yi Wang [1], Antoine Iannessi [1] - Affiliations: [1] Median Technologies, Valbonne, France

Poster presented at the ASCO Annual Meeting – June 4-6, 2022.

The objectives of this work are to document the proportion of reader discrepancies, to evaluate reader performance and to provide suggestions for the reduction of read inconsistency.

iBiopsy® Lung Cancer Screening: a unique AI powered end to end CADe CADx SaMD for early diagnosis

Yan Liu [1], Benoit Huet [1] – Affiliations: [1] Median Technologies, 1800 Route des Crêtes, 06560 Valbonne, France.

Présenté le 28 Nov. 2021 au RSNA AI Theater – Réunion annuelle du RSNA, 28 Nov. – 2 Déc. 2021, à Chicago, IL, USA. Cette présentation apporte une vision de la performance d’iBiopsy® Lung Cancer Screening CADx portant spécifiquement sur la caractérisation du cancer pulmonaire de stade 1.

Blinded Independent Central Review (BICR) in New Therapeutic Lung Cancer Trials

Hubert Beaumont [1] , Antoine Iannessi [1, 2], Yi Wang [1], Charles M. Voyton [1], Jennifer Cillario [1], Yan Liu [1] – Affiliations: [1] Median Technologies, 1800 Route des Crêtes, 06560 Valbonne, France. [2] Centre Antoine Lacassagne, 33 Avenue de Valombrose, 06100 Nice, France

The aim of this study was to analyze a pool of lung trials that used RECIST 1.1, document the proportion of reader discrepancies and the reader performance through monitoring procedures, and provide suggestions for the reduction of read inconsistency.

See publication